Diagnostic laboratory tests
Diagnostic laboratory tests from Inmodia GmbH for the clarification and documentation of possible COVID-19 vaccine damage
Brief info
- Possible biomaterial: biopsies (including tumour samples), autopsies, blood, cerebrospinal fluid
- Detection of spike proteins and additional tests to differentiate between infection-related long COVID and vaccine damage
- Standardised and innovative methods; up to 1000 times more sensitive than conventionally used tests
- Focus of testing is Pfizer/BioNTech and Moderna; for Astra-Zeneca and Janssen/Johnson & Johnson only general spike protein detection possible for the time being
- Self-payers
Submissions:
Mon-May, after consultation and completion of the declaration of consent
Contact:
- Tel.: +49 851 – 2042 5681 (Mon-Fri 9-11am; Mon-Thu 5-7pm)
- Email: ‘meldestelle_at_inmodia.de’:javascript:decryptUnicorn(zryqrfgryyr|vazbqvn.qr
The Institute of Molecular Diagnostics (Inmodia GmbH) offers detection of all components of RNA-based injections:
- Spike protein
- ‘Vaccine mRNA’ (modRNA)
- residual DNA (plasmid DNA)
These components can be detected in the following sample materials:
- Tissue samples (biopsy or autopsy materials, fixed or unfixed)
- Blood plasma
- Cerebrospinal fluid
- Immune cells from whole blood or cerebrospinal fluid
Specific detection methods for DNA-based injections are currently not offered, as they have hardly been used in Germany. However, the methods for detecting spike protein also cover these injections.
In the case of RNA-based injections, the laboratory must be informed whether the vaccine was injected by Pfizer / BioNTech or by Moderna, as specific reagents must be used for diagnostics in each case.